Search Result

Results for "

full agonist

" in MedChemExpress (MCE) Product Catalog:

By Targets:	5-HT Receptor (28) Adenosine Receptor (4) Adenylate Cyclase (1) Adrenergic Receptor (22) Amyloid-β (1) Angiotensin Receptor (1) Apelin Receptor (APJ) (1) Apoptosis (1) Arrestin (4) Cannabinoid Receptor (7) Cholecystokinin Receptor (2) Cytochrome P450 (1) Dopamine Receptor (27) Drug Intermediate (1) Endogenous Metabolite (4) Environmental Pollutants (2) ERK (7) Estrogen Receptor/ERR (6) FAAH (1) Free Fatty Acid Receptor (9) FXR (1) GABA Receptor (8) GHR (1) GHSR (3) Glucokinase (1) Glycosyltransferase (1) GnRH Receptor (1) GPR109A (6) GPR52 (1) HCN Channel (1) Histamine Receptor (10) IGF-1R (1) iGluR (1) Insulin Receptor (4) Interleukin Related (2) Isotope-Labeled Compounds (17) Kisspeptin Receptor (5) Leukotriene Receptor (2) LPL Receptor (1) LXR (2) mAChR (6) Melanocortin Receptor (3) mGluR (1) MMP (2) nAChR (26) Neurokinin Receptor (2) Neuropeptide FF Receptor (4) Neuropeptide Y Receptor (1) Neurotensin Receptor (3) NF-κB (1) Opioid Receptor (11) Orphan GPCR (1) Orphan Nuclear Receptor (1) P2Y Receptor (1) p38 MAPK (8) PARP (1) PGC-1α (1) Phosphatase (1) Potassium Channel (1) PPAR (9) Progesterone Receptor (1) Prostaglandin Receptor (7) Protease Activated Receptor (PAR) (1) PTHR (2) RAR/RXR (1) Reference Standards (27) ROR (1) Somatostatin Receptor (1) TNF Receptor (1) Toll-like Receptor (TLR) (1) Trace Amine-associated Receptor (TAAR) (2) TSH Receptor (1) YAP (1)
By Research Areas:	Cancer (31) Cardiovascular Disease (15) Endocrinology (32) Infection (1) Inflammation/Immunology (34) Metabolic Disease (51) Neurological Disease (107)
Click Chemistry:	Alkynes (1)

210

Inhibitors & Agonists

Peptides

Natural
Products

Isotope-Labeled Compounds

Click Chemistry

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-10629

LXR-623 10+ Cited Publications WAY 252623	LXR	Metabolic Disease Cancer
LXR-623 is a brain-penetrant partial LXRα and full LXRβ agonist, with IC₅₀s of 24 nM and 179 nM, respectively.

HY-10019

Varenicline 1 Publications Verification CP 526555	nAChR	Neurological Disease Inflammation/Immunology Cancer
Varenicline (CP 526555) is an orally active partial agonist of α4β2 nicotinic acetylcholine receptor (α4β2 nAChR, IC₅₀ = 250 nM), which is the principal mediator of nicotine dependence. Varenicline is also a partial agonist of α6β2 nAChR and a full agonist of α7β2 nAChR. Varenicline blocks the direct agonist effects of nicotine on nAChR while stimulates nAChR in a more moderate way, being widely used as an aid of smoking cessation .

HY-N0175

Cytisinicline 1 Publications Verification Cytisine; Sophorine; Baptitoxine	nAChR	Metabolic Disease Cancer
Cytisinicline (Cytisine) is an alkaloid. Cytisinicline (Cytisine) is a partial agonist of α4β2 nAChRs , and partial to full agonist at β4 containing receptors and α7 receptors . Has been used medically to help with smoking cessation .

HY-10021

Varenicline Tartrate 1 Publications Verification CP 526555-18	nAChR ERK p38 MAPK	Others Neurological Disease Cancer
Varenicline (CP 526555) is an orally active partial agonist of α4β2 nicotinic acetylcholine receptor (α4β2 nAChR, IC₅₀ = 250 nM), which is the principal mediator of nicotine dependence. Varenicline is also a partial agonist of α6β2 nAChR and a full agonist of α6β2 nAChR. Varenicline blocks the direct agonist effects of nicotine on nAChR while stimulates nAChR in a more moderate way, being widely used as an aid of smoking cessation .

HY-100856

PCO371	PTHR	Endocrinology
PCO371 is an orally active full agonist of parathyroid hormone receptor 1 (PTHR1), with no effect on PTH type 2 receptor.

HY-132265

SCO-267 3 Publications Verification	Free Fatty Acid Receptor	Metabolic Disease
SCO-267 is an allosteric GPR40 full agonist. SCO-267 can be used for the research of chronic diseases including diabetes .

HY-121251

BI-167107 2 Publications Verification	Adrenergic Receptor	Neurological Disease Endocrinology Cancer
BI-167107 is a high affinity, full agonist that binds to the β2 adrenergic receptor (β2AR) with a dissociation constant K_d of 84 pM .

HY-147105

LRH-1 agonist-2	Orphan Nuclear Receptor Interleukin Related	Inflammation/Immunology
LRH-1 agonist-2 (Compound 6N) is a selective, full LRH-1 agonist with an EC₅₀ of 15.7 nM. LRH-1 agonist-2 directly interacts with the Thr352 and His390 residues in the LRH-1 binding pocket, promotes allosteric signaling to the activation function surface (AFS), stabilizes the AFS and enhances coactivator recruitment. LRH-1 agonist-2 induces the anti-inflammatory cytokine IL-10, and reduces the pro-inflammatory cytokines IL-1β and TNFα. LRH-1 modulator-1 exerts anti-inflammatory effects in intestinal organoids. LRH-1 modulator-1 can be used in studies related to inflammatory bowel disease .

HY-10680

MK-6892 5+ Cited Publications	GPR109A	Cancer
MK-6892 is a potent, selective, and full agonist for the high affinity nicotinic acid (NA) receptor GPR109A. K_i and GTPγS EC₅₀ of MK-6892 on the Human GPR109A is 4 nM and 16 nM, respectively.

HY-A0007

Rotigotine Hydrochloride 3 Publications Verification N-0923 Hydrochloride	Dopamine Receptor Adrenergic Receptor 5-HT Receptor	Neurological Disease
Rotigotine Hydrochloride (N-0923 Hydrochloride) is a full agonist of dopamine receptor, a partial agonist of the 5-HT1A receptor, and an antagonist of the α2B-adrenergic receptor, with K_i of 0.71 nM, 4-15 nM, and 83 nM for the dopamine D3 receptor and D2, D5, D4 receptors, and dopamine D1 receptor.

HY-10233

Gaboxadol hydrochloride 1 Publications Verification Lu 02-030 hydrochloride; THIP hydrochloride	GABA Receptor	Neurological Disease
Gaboxadol hydrochloride (Lu 02-030 hydrochloride) is a potent agonist of the GABA_A receptor and an antagonist of GABA_C receptors (IC₅₀=25 μM). Gaboxadol hydrochloride displays a partial agonist efficacy on subunit α1β2γ2 with an ED₅₀ value of 143 μM, a full agonist efficacy at α5 subunit (ED₅₀=28-129 μM) and a superagonist efficacy at α4β3δ (ED₅₀=6 μM). Gaboxadol hydrochloride is a non-opioid agent .

HY-B0659

Brimonidine 5+ Cited Publications UK 14304; AGN190342	Adrenergic Receptor	Cardiovascular Disease Endocrinology Cancer
Brimonidine (UK 14304) is a full α2-adrenergic receptor (α2-AR) agonist.

HY-B0659A

Brimonidine tartrate 5+ Cited Publications UK 14304 tartrate; AGN190342 tartrate	Adrenergic Receptor	Cardiovascular Disease Endocrinology Cancer
Brimonidine tartrate (UK 14304 tartrate) is a full α2-adrenergic receptor (α2-AR) agonist.

HY-114116

ML-109	TSH Receptor	Metabolic Disease Endocrinology
ML-109 is a potent and full thyroid stimulating hormone receptor (TSHR) agonist, with an EC₅₀ of 40 nM.

HY-13788

LY 344864 2 Publications Verification	5-HT Receptor Adrenergic Receptor	Neurological Disease
LY 344864 is a selective, orally active 5-HT_1F receptor agonist with a K_i of 6 nM. LY 344864 is a full agonist producing an effect similar in magnitude to serotonin itself. LY 344864 can cross the blood brain barrier to some extent .

HY-B0584

Travoprost 3 Publications Verification Fluprostenol isopropyl ester; AL6221; Flu-Ipr	Prostaglandin Receptor	Cardiovascular Disease Endocrinology
Travoprost (Fluprostenol isopropyl ester), an isopropyl ester proagent, is a high affinity, selective FP prostaglandin full receptor agonist. Travoprost has the ocular hypotensive efficacy and has the potential for glaucoma and ocular hypertension .

HY-10020

Varenicline Hydrochloride CP 526555 hydrochloride	nAChR	Neurological Disease Inflammation/Immunology Cancer
Varenicline (CP 526555) is an orally active partial agonist of α4β2 nicotinic acetylcholine receptor (α4β2 nAChR, IC₅₀ = 250 nM), which is the principal mediator of nicotine dependence. Varenicline is also a partial agonist of α6β2 nAChR and a full agonist of α6β2 nAChR. Varenicline blocks the direct agonist effects of nicotine on nAChR while stimulates nAChR in a more moderate way, being widely used as an aid of smoking cessation .

HY-14340

WAY-181187 2 Publications Verification SAX-187	5-HT Receptor	Neurological Disease
WAY-181187 (SAX-187) is a potent and selective full 5-HT6 receptor agonist with a K_i of 2.2 nM and an EC₅₀ of 6.6 nM . WAY181187 mediates 5-HT6 receptor-dependent signal pathways, such as cAMP, Fyn and ERK1/2 kinase, as specific agonist .

HY-101300

Cirazoline hydrochloride LD 3098 hydrochloride	Adenosine Receptor	Neurological Disease
Cirazoline hydrochloride (LD 3098 hydrochloride) is a potent competitive full α1A-adrenergic receptor (α1A-AR) agonist (K_i=120 nM) and only a partial agonist at α1B-AR (K_i= 960 nM) and α1D-AR (K_i=660 nM) .

HY-100369A

DMCM hydrochloride	GABA Receptor	Neurological Disease
DMCM hydrochloride is a nonselective full inverse agonist of benzodiazepine. DMCM shows bnding afinity at human recombinant GABAA αxβ3γ2 receptor subtypes with K_is of 10 nM, 13 nM, 7.5 nM, 2.2 nM for α1, α2, α3, and α5 receptors, respectively .

HY-N5016

Guvacoline hydrochloride	mAChR	Cardiovascular Disease
Guvacoline hydrochloride, a pyridine alkaloid found in Areca triandra, can act as a weak full agonist of atrial and ileal muscarinic receptors .

HY-P0076A

TAK-448 acetate 3 Publications Verification MVT-602 acetate	Kisspeptin Receptor	Cancer
TAK-448 acetate (MVT-602 acetate) is a potent and full KISS1R agonist with an IC₅₀ of 460 pM and an EC₅₀ of 632 pM .

HY-P0076

TAK-448 3 Publications Verification MVT-602	Kisspeptin Receptor	Cancer
TAK-448 (MVT-602) is a potent and full KISS1R agonist with an IC₅₀ of 460 pM and an EC₅₀ of 632 pM .

HY-16619

AM-5262	Free Fatty Acid Receptor	Metabolic Disease
AM-5262 is a GPR40 full agonist with an EC₅₀ value of 0.081 μM. AM-5262 can be used for the research of type II diabetes .

HY-P10377

GUB03385	Neuropeptide FF Receptor	Metabolic Disease
GUB03385 is a long-acting PrRP31 analogue. GUB03385 is a potent dual agonist for GPR10 (full agonist, EC₅₀: 0.4 nM) and NPFF2R (partial agonist, EC₅₀: 20 nM). GUB03385 has anti-obesity effect .

HY-114871

SL651498	GABA Receptor	Neurological Disease
SL651498 is a full agonist of α2 and α3 GABAA receptors, and a partial agonist of α1 and α5 GABAA receptors. SL651498 shows anxiolytic and anticonvulsant activities .

HY-10019A

Varenicline dihydrochloride CP 526555 dihydrochloride	nAChR	Neurological Disease Inflammation/Immunology Cancer
Varenicline (CP 526555-18) is an orally active partial agonist of α4β2 nicotinic acetylcholine receptor (α4β2 nAChR, IC₅₀ = 250 nM), which is the principal mediator of nicotine dependence. Varenicline is also a partial agonist of α6β2 nAChR and a full agonist of α7β2 nAChR. Varenicline blocks the direct agonist effects of nicotine on nAChR while stimulates nAChR in a more moderate way, being widely used as an aid of smoking cessation .

HY-P2197

ELA-11(human)	Apelin Receptor (APJ) Arrestin	Inflammation/Immunology
ELA-11(human), a peptide, is a full agonist of human apelin receptor, with a pK_i of 7.85. ELA-11(human) completely inhibits Forskolin-induced cAMP production and stimulates β-arrestin recruitment .

HY-155318A

GPR3 agonist-2	Orphan GPCR	Endocrinology
GPR3 agonist-2(compound 32) is a potent full agonist of G protein-coupled receptor 3, with the IC₅₀of 260 nM .

HY-116490

Guvacoline hydrobromide	mAChR	Cardiovascular Disease
Guvacoline hydrobromide, a pyridine alkaloid found in Areca triandra, can act as a weak full agonist of atrial and ileal mAChR .

HY-128855

Talsaclidine	mAChR	Neurological Disease
Talsaclidine is a muscarinic agonist with preferential neuron-stimulating properties. Talsaclidine is a full agonist at the M1 subtype, and as a partial agonist at the M2 and M3 subtypes . Talsaclidine is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.

HY-114060

CFMB	Free Fatty Acid Receptor	Metabolic Disease
CFMB is a full agonist of FFAR2- and FFAR3-specific with EC₅₀ value of 0.8 μM target hFFAR2 and 0.2 μM target rFFAR2 .

HY-N0175R

Cytisinicline (Standard) Cytisine (Standard); Sophorine (Standard); Baptitoxine (Standard)	Reference Standards nAChR	Metabolic Disease Cancer
Cytisinicline (Standard) is the analytical standard of Cytisinicline. This product is intended for research and analytical applications. Cytisinicline (Cytisine) is an alkaloid. Cytisinicline (Cytisine) is a partial agonist of α4β2 nAChRs , and partial to full agonist at β4 containing receptors and α7 receptors . Has been used medically to help with smoking cessation .

HY-15394

(Rac)-Rotigotine hydrochloride N-0437 hydrochloride	Dopamine Receptor Adrenergic Receptor 5-HT Receptor	Neurological Disease Endocrinology
(Rac)-Rotigotine hydrochloride is a racemate of Rotigotine. Rotigotine is a full agonist of dopamine receptor, a partial agonist of the 5-HT1A receptor, and an antagonist of the α2B-adrenergic receptor, with K_is of 0.71 nM, 4-15 nM, and 83 nM for the dopamine D3 receptor and D2, D5, D4 receptors, and dopamine D1 receptor.

HY-108499

NNC 26-9100	Somatostatin Receptor Amyloid-β	Neurological Disease
NNC 26-9100 is a selective somatostatin sst4 receptor full agonist (K_i: 6 nM, EC₅₀: 2 nM). NNC 26-9100 decreases total soluble Aβ42, increases brain neprilysin activity and improves learning .

HY-145364

*Ghrelin receptor full* agonist-2**	GHSR	Metabolic Disease
Ghrelin receptor full agonist-2 (compound 12j) is a highly potent Ghrelin receptor full agonist.

HY-108991

T-0509 (-)-T-0509	Adrenergic Receptor	Cardiovascular Disease
T-0509 ((-)-T-0509) is a selective full agonist of the β₁ receptor. T-0509 activates the cAMP signaling pathway through the β₁ receptor and enhances myocardial contractility .

HY-19942A

TD-5471 hydrochloride	Adrenergic Receptor	Metabolic Disease Endocrinology
TD-5471 hydrochloride is a potent and selective full agonist of the human β₂-adrenoceptor.

HY-135432

Etrasimod arginine 1 Publications Verification APD334 arginine	LPL Receptor	Inflammation/Immunology
Etrasimod arginine is an orally available S1P receptor modulator that is a potent full agonist of the S1P1 receptor and has partial agonist activity at S1P4. Etrasimod arginine reduces inflammation in a CD4 ⁺CD45RB ^high T cell-transferred mouse colitis model .

HY-B0659S

Brimonidine-d4	Adrenergic Receptor	Endocrinology
Brimonidine-d₄ is the deuterium labeled Brimonidine. Brimonidine (UK 14304) is a full α2-adrenergic receptor (α2-AR) agonist.

HY-P3910

[Val4] Angiotensin III	Angiotensin Receptor	Cardiovascular Disease
[Val4] Angiotensin III is an angiotension III peptide. [Val4] Angiotensin III is a potent full agonist of Gα_q and βarr2 response, with pEC₅₀ values of 8.31 and 8.44, respectively .

HY-128040

Virodhamine hydrochloride	Endogenous Metabolite Cannabinoid Receptor	Neurological Disease
Virodhamine (hydrochloride) is a cannabinoid CB1 receptor partial agonist and cannabinoid CB2 receptor full agonist .

HY-P1198

Hemokinin 1, human	Neurokinin Receptor	Neurological Disease
Hemokinin 1, human is a selective tachykinin neurokinin 1 (NK1) receptor full agonist. Hemokinin 1, human is a full agonist at NK2 and NK3 receptor. Hemokinin 1, human can produces an opioid-independent analgesia .

HY-101609

Lesopitron dihydrochloride E4424	5-HT Receptor	Neurological Disease
Lesopitron dihydrochloride is a full and selective 5-HT_1A receptor agonist with IC₅₀ of 125 nM in rat hippocampal membranes.

HY-175490

RORγ inverse agonist 2	ROR	Inflammation/Immunology
RORγ inverse agonist 2 (Compound 15) is a potent inverse agonist of the retinoic acid receptor-related orphan receptor RORγ, with IC₅₀ values of 0.4 and 0.9 μM for Gal4-RORγ and full-length RORγ, respectively. RORγ inverse agonist 2 is useful in the study of autoimmune diseases .

HY-P5131

[Dmt1]DALDA	Opioid Receptor	Others
[Dmt1]DALDA is a potent and long-acting analgesic binds to the mu opioid receptor with high affinity and selectivity. [Dmt1]DALDA is a full agonist at hMOR (K_d = 0.199 nM) and hDOR, but only partial agonist against hKOR .

HY-154829A

AC-099 hydrochloride	Neuropeptide FF Receptor	Inflammation/Immunology
AC-099 hydrochloride (compound 3) is a selective NPFF2R full agonist (EC₅₀=1189 nM) and NPFF1R partial agonist (EC₅₀=2370 nM). AC-099 hydrochloride attenuates spinal nerve ligation-induced hypersensitivity in rats .

HY-105634

Nomegestrol	Progesterone Receptor	Endocrinology Cancer
Nomegestrol is a potent and orally available progestin, acts as a selective full progesterone receptor agonist, with a K_d of 5.44 nM for rat uterine progesterone receptor, and has moderate antiandrogenic activity and strong antiestrogenic activity.

HY-W746031

WAY-181187 hydrochloride SAX-187 hydrochloride	5-HT Receptor	Neurological Disease
WAY-181187 (SAX-187) hydrochloride is a potent and selective full 5-HT6 receptor agonist with a K_i of 2.2 nM and an EC₅₀ of 6.6 nM . WAY-181187 hydrochloride mediates 5-HT6 receptor-dependent signal pathways, such as cAMP, Fyn and ERK1/2 kinase, as specific agonist .

HY-P3876

(Pro34)-Peptide YY (human)	Neuropeptide Y Receptor	Neurological Disease
(Pro34)-Peptide YY (human) is a highly Y₁-selective full agonist of Peptide YY (HY-P1514)/neuropeptide Y receptors .

Cat. No.	Product Name	Target	Research Area

HY-P1096

A71623	Cholecystokinin Receptor	Metabolic Disease
A71623, a CCK-4-based peptide, is a potent and highly selective CCK-A full agonist. The IC₅₀s for A-71623 are 3.7 nM in guinea pig pancreas (CCK-A) and 4500 nM in cerebral cortex (CCK-B) in radioligand binding assays, respectively .

HY-P2161B

TAK-683 acetate 4 Publications Verification	Kisspeptin Receptor	Cancer
TAK-683 acetate is a potent full KISS1 receptor (KISS1R) agonist (IC₅₀=170 pM) with improved metabolic stability. TAK-683 acetate is a nonapeptide metastin analog, exhibits agonistic activities to KISS1R with EC₅₀ values of 0.96 nM and 1.6 nM for human and rat, respectively . TAK-683 acetate depletes GnRH in the hypothalamus and reduces plasma FSH, LH, and testosterone levels in vivo, it has the potential for the study of hormone-dependent prostate cancer .

HY-P0076A

TAK-448 acetate 3 Publications Verification MVT-602 acetate	Kisspeptin Receptor	Cancer
TAK-448 acetate (MVT-602 acetate) is a potent and full KISS1R agonist with an IC₅₀ of 460 pM and an EC₅₀ of 632 pM .

HY-P0076

TAK-448 3 Publications Verification MVT-602	Kisspeptin Receptor	Cancer
TAK-448 (MVT-602) is a potent and full KISS1R agonist with an IC₅₀ of 460 pM and an EC₅₀ of 632 pM .

HY-P10377

GUB03385	Neuropeptide FF Receptor	Metabolic Disease
GUB03385 is a long-acting PrRP31 analogue. GUB03385 is a potent dual agonist for GPR10 (full agonist, EC₅₀: 0.4 nM) and NPFF2R (partial agonist, EC₅₀: 20 nM). GUB03385 has anti-obesity effect .

HY-P2197

ELA-11(human)	Apelin Receptor (APJ) Arrestin	Inflammation/Immunology
ELA-11(human), a peptide, is a full agonist of human apelin receptor, with a pK_i of 7.85. ELA-11(human) completely inhibits Forskolin-induced cAMP production and stimulates β-arrestin recruitment .

HY-P2541A

GIP (1-30) amide, porcine TFA	Insulin Receptor	Metabolic Disease
GIP (1-30) amide, porcine TFA is a full glucose-dependent insulinotropic polypeptide (GIP) receptor agonist with high affinity equal to native GIP(1-42) . GIP (1-30) amide, porcine is a weak inhibitor of gastric acid secretion and potent stimulator of insulin.

HY-P3584A

(Pro3) GIP, human TFA (Pro3) Gastric Inhibitory Peptide, human TFA	Insulin Receptor	Metabolic Disease
(Pro3) GIP, human TFA is an efficacious, stable and specific human GIP receptor (hGIPR) full agonist. (Pro3) GIP, human TFA has high binding affinity for human GIPR with K_i/ K_d value of 0.90 nM. (Pro3) GIP, human TFA human can be used for the research of obesity-related diabetes .

HY-P3910

[Val4] Angiotensin III	Angiotensin Receptor	Cardiovascular Disease
[Val4] Angiotensin III is an angiotension III peptide. [Val4] Angiotensin III is a potent full agonist of Gα_q and βarr2 response, with pEC₅₀ values of 8.31 and 8.44, respectively .

HY-P3584

(Pro3) GIP, human (Pro3) Gastric Inhibitory Peptide, human	Insulin Receptor	Metabolic Disease
(Pro3) GIP, human ((Pro3) Gastric Inhibitory Peptide, human) is an efficacious, stable and specific human GIP receptor (hGIPR) full agonist. (Pro3) GIP, human has high binding affinity for human GIPR with K_i/ K_d values of 0.90 nM. (Pro3) GIP, human can be used for the research of obesity-related diabetes .

HY-P2161

TAK-683	Kisspeptin Receptor	Cancer
TAK-683 is a potent full KISS1 receptor (KISS1R) agonist (IC₅₀=170 pM) with improved metabolic stability. TAK-683 is a nonapeptide metastin analog, exhibits agonistic activities to KISS1R with EC₅₀ values of 0.96 nM and 1.6 nM for human and rat, respectively . TAK-683 depletes GnRH in the hypothalamus and reduces plasma FSH, LH, and testosterone levels in vivo, it has the potential for the study of hormone-dependent prostate cancer .

HY-P1198

Hemokinin 1, human	Neurokinin Receptor	Neurological Disease
Hemokinin 1, human is a selective tachykinin neurokinin 1 (NK1) receptor full agonist. Hemokinin 1, human is a full agonist at NK2 and NK3 receptor. Hemokinin 1, human can produces an opioid-independent analgesia .

HY-P5131

[Dmt1]DALDA	Opioid Receptor	Others
[Dmt1]DALDA is a potent and long-acting analgesic binds to the mu opioid receptor with high affinity and selectivity. [Dmt1]DALDA is a full agonist at hMOR (K_d = 0.199 nM) and hDOR, but only partial agonist against hKOR .

HY-P3876

(Pro34)-Peptide YY (human)	Neuropeptide Y Receptor	Neurological Disease
(Pro34)-Peptide YY (human) is a highly Y₁-selective full agonist of Peptide YY (HY-P1514)/neuropeptide Y receptors .

HY-P2541

GIP (1-30) amide, porcine	Insulin Receptor	Metabolic Disease
GIP (1-30) amide, porcine is a full glucose-dependent insulinotropic polypeptide (GIP) receptor agonist with high affinity equal to native GIP(1-42) . GIP (1-30) amide, porcine is a weak inhibitor of gastric acid secretion and potent stimulator of insulin.

HY-P11469

PG-901	Melanocortin Receptor Interleukin Related	Neurological Disease Metabolic Disease Inflammation/Immunology
PG-901 is a full, selective MC5R agonist (EC₅₀ = 0.072 nM for hMC5R). PG-901 is also a full antagonist at the hMC3R and the hMC4R (K_b: 1.0 nM and 0.53 nM, respectively). PG-901 significantly diminishes Cytokines (IL-1α, IL-1β, IL-6). PG-901 increases glucose tolerance, reduces blood glucose, decreases retinal damage .

HY-149941

hNTS1R agonist-1	Neurotensin Receptor	Neurological Disease
hNTS1R agonist-1 (Compound 10) is a BBB permeable hNTS1R full agonist (K_i: 6.9 nM) . hNTS1R agonist-1 increases motor function and memory in a mouse model of Parkinson's disease (PD). hNTS1R agonist-1 is a Neurotensin(8-13) analog and is a neuroprotective agent .

HY-P1198A

Hemokinin 1, human TFA	Neurokinin Receptor	Neurological Disease
Hemokinin 1, human TFA is a selective tachykinin neurokinin 1 (NK1) receptor full agonist. Hemokinin 1, human TFA is a full agonist at NK2 and NK3 receptor. Hemokinin 1, human TFA can produces an opioid-independent analgesia .

HY-110366

WAY-181187 oxalate SAX-187 oxalate	5-HT Receptor	Neurological Disease
WAY-181187 (SAX-187) oxalate is a potent and selective full 5-HT6 receptor agonist with a K_i of 2.2 nM and an EC₅₀ of 6.6 nM. WAY-181187 oxalate mediates 5-HT6 receptor-dependent signal pathways, such as cAMP, Fyn and ERK1/2 kinase, as specific agonist .

HY-P3057

[D-Trp11]-Neurotensin	Neurotensin Receptor	Cardiovascular Disease Neurological Disease
[D-Trp11]-Neurotensin, an analogue of Neurotensin (NT), is a selective antagonist of NT in perfused rat hearts but behaves as a full agonist in guinea pig atria and rat stomach strips. [D-Trp11]-Neurotensin can inhibit NT-induced hypotension .

HY-P2380

PAR3 (1-6) (human) TFRGAP	Protease Activated Receptor (PAR)	Inflammation/Immunology
PAR3 (1-6) is a synthetic peptide agonist of proteinase-activated receptor 1 (PAR1) that corresponds to residues 1-6 of the amino terminal tethered ligand sequence of human PAR3 and residues 39-44 of the full-length human sequence. PAR3 (1-6) activates p42/44 MAPK signaling in fibroblasts expressing PAR1, but not PAR3, an effect that can be blocked by the PAR1 antagonist RWJ 56110.

HY-P2161A

TAK-683 TFA	Kisspeptin Receptor	Cancer
TAK-683 TFA is a potent full KISS1 receptor (KISS1R) agonist (IC₅₀=170 pM) with improved metabolic stability. TAK-683 TFA is a nonapeptide metastin analog, exhibits agonistic activities to KISS1R with EC₅₀ values of 0.96 nM and 1.6 nM for human and rat, respectively . TAK-683 TFA depletes GnRH in the hypothalamus and reduces plasma FSH, LH, and testosterone levels in vivo, it has the potential for the study of hormone-dependent prostate cancer .

HY-P11810

GUB08248	GnRH Receptor Neuropeptide FF Receptor	Metabolic Disease
GUB08248 is a full GPR10 agonist and a partial NPFF2R agonist, with EC₅₀ values of 0.5 nM and 2.5 nM, respectively. GUB08248 inhibits food intake and induces sustained weight loss. GUB08248 can be used in obesity-related research .

HY-P11432

PG-911	Melanocortin Receptor	Neurological Disease
PG-911 is a full MC5R agonist (EC₅₀ = 0.031 nM for hMC5R). PG-911 is also a full antagonist at the hMC3R and the hMC4R (K_b: 0.38 nM and 0.17 nM, respectively). PG-911 can be used in the research of neurological disorders .

Cat. No.	Product Name	Category	Target	Chemical Structure

HY-N0175

Cytisinicline 1 Publications Verification Cytisine; Sophorine; Baptitoxine	Alkaloids Classification of Application Fields Leguminosae Pyridine Alkaloids Metabolic Disease Plants Thermopsis lanceolala R.Br. Disease Research Fields Source Classification	nAChR
Cytisinicline (Cytisine) is an alkaloid. Cytisinicline (Cytisine) is a partial agonist of α4β2 nAChRs , and partial to full agonist at β4 containing receptors and α7 receptors . Has been used medically to help with smoking cessation .

HY-B0188A

Mianserin hydrochloride 1 Publications Verification Org GB 94	Alkaloids Structural Classification Neurological Disease Classification of Application Fields Leguminosae Other Alkaloids Crotalaria pallida Ait. Plants Disease Research Fields Endocrinology Source Classification	Histamine Receptor Opioid Receptor ERK p38 MAPK
Mianserin hydrochloride (Org GB 94) is an orally active H1 receptor antagonist. Mianserin hydrochloride can activate κ-opioid receptor and octopamine receptor. Mianserin hydrochloride increases ERK1/2 and CREB phosphorylation, and antagonizes full κ-opioid agonist and Dynorphin A (HY-P1333)-induced MAPK phosphorylation. Mianserin hydrochloride modulates social and exploratory behaviour, raises electroconvulsive thresholds. Mianserin hydrochloride can be used for the research of neurological disease, such as depression and epilepsy .

HY-113413

Imidazoleacetic acid 2 Publications Verification Imidazolyl-4-acetic acid	Structural Classification Human Gut Microbiota Metabolites Classification of Application Fields Ketones, Aldehydes, Acids Metabolic Disease Endogenous metabolite Disease Research Fields Source Classification	Endogenous Metabolite GABA Receptor
Imidazoleacetic acid (Imidazolyl-4-acetic acid) is a blood-brain barrier-permeable full agonist of the GABA_A receptor. Imidazoleacetic acid forms via histamine oxidation in the mouse brain. Imidazoleacetic acid exerts multiple neurochemical and behavioral effects. Imidazoleacetic acid induces a range of centrally mediated effects, including analgesia, sedation, hypnosis, as well as reductions in blood pressure, body temperature, isolation-induced aggression and motor activity .

HY-B1532

Anabasine (S)-Anabasine; (+)-Anabasine	Alkaloids Piperidine Alkaloids Structural Classification Nicotiana tabacum L. Pyridine Alkaloids Solanaceae Plants Source Classification	Environmental Pollutants nAChR
Anabasine ((S)-Anabasine) is an alkaloid that found as a minor component in tobacco (Nicotiana). Anabasine is a botanical pesticide nicotine, acts as a full agonist of nicotinic acetylcholine receptors (nAChRs). Anabasine induces depolarization of TE671 cells endogenously expressing human fetal muscle-type nAChRs (EC₅₀=0.7 μM) .

HY-N5016

Guvacoline hydrochloride	Cardiovascular Disease Alkaloids Classification of Application Fields Pyridine Alkaloids Plants Palmae Areca triandra Roxb. Disease Research Fields Source Classification	mAChR
Guvacoline hydrochloride, a pyridine alkaloid found in Areca triandra, can act as a weak full agonist of atrial and ileal muscarinic receptors .

HY-N0175R

Cytisinicline (Standard) Cytisine (Standard); Sophorine (Standard); Baptitoxine (Standard)	Alkaloids Structural Classification Leguminosae Pyridine Alkaloids Plants Thermopsis lanceolala R.Br. Source Classification	Reference Standards nAChR
Cytisinicline (Standard) is the analytical standard of Cytisinicline. This product is intended for research and analytical applications. Cytisinicline (Cytisine) is an alkaloid. Cytisinicline (Cytisine) is a partial agonist of α4β2 nAChRs , and partial to full agonist at β4 containing receptors and α7 receptors . Has been used medically to help with smoking cessation .

HY-148596

UDP-GlcNAc UDP-N-Acetyl-D-glucosamine; Uridine diphospho-N-acetylglucosamine; UDP-N-acetylglucosamine	Human Gut Microbiota Metabolites Microorganisms Endogenous metabolite Source Classification	Endogenous Metabolite P2Y Receptor Drug Intermediate Glycosyltransferase
UDP-GlcNAc (UDP-N-Acetyl-D-glucosamine) is an important component and precursor of bacterial peptidoglycan. UDP-GlcNAc is a nucleotide sugar used by Glycosyltransferases to synthesize glycoproteins, glycosaminoglycans, glycolipids, and glycoRNA. UDP-GlcNAc also serves as the donor substrate for forming O-GlcNAc, a dynamic intracellular protein modification involved in diverse signaling and disease processes. UDP-GlcNAc is the sugar nucleotide donor for the synthesis of O-GlcNAc modified proteins. UDP-GlcNAc also acts as a full agonist of the P2Y₁₄ receptor and inhibits the formation of cAMP. UDP-GlcNAc can be used in studies related to bacterial infections .

HY-B0188AR

Mianserin hydrochloride (Standard) Org GB 94 (Standard)	Alkaloids Structural Classification Leguminosae Other Alkaloids Crotalaria pallida Ait. Plants Source Classification	Reference Standards Histamine Receptor Opioid Receptor ERK p38 MAPK
Mianserin hydrochloride (Org GB 94) (Standard) is the analytical standard of Mianserin hydrochloride. This product is intended for research and analytical applications. Mianserin hydrochloride is an orally active H1 receptor antagonist. Mianserin hydrochloride can activate κ-opioid receptor and octopamine receptor. Mianserin hydrochloride increases ERK1/2 and CREB phosphorylation, and antagonizes full κ-opioid agonist and Dynorphin A (HY-P1333)-induced MAPK phosphorylation. Mianserin hydrochloride modulates social and exploratory behaviour, raises electroconvulsive thresholds. Mianserin hydrochloride can be used for the research of neurological disease, such as depression and epilepsy .

HY-B1532R

Anabasine (Standard) (S)-Anabasine (Standard); (+)-Anabasine (Standard)	Alkaloids Piperidine Alkaloids Structural Classification Nicotiana tabacum L. Pyridine Alkaloids Solanaceae Plants Source Classification	Reference Standards nAChR
Anabasine (Standard) is the analytical standard of Anabasine. This product is intended for research and analytical applications. Anabasine ((S)-Anabasine) is an alkaloid that found as a minor component in tobacco (Nicotiana). Anabasine is a botanical pesticide nicotine, acts as a full agonist of nicotinic acetylcholine receptors (nAChRs). Anabasine induces depolarization of TE671 cells endogenously expressing human fetal muscle-type nAChRs (EC₅₀=0.7 μM) .

HY-113413R

Imidazoleacetic acid (Standard) Imidazolyl-4-acetic acid (Standard)	Structural Classification Human Gut Microbiota Metabolites Microorganisms Ketones, Aldehydes, Acids Endogenous metabolite Source Classification	Reference Standards Endogenous Metabolite GABA Receptor
Imidazoleacetic acid (Standard) is the analytical standard of Imidazoleacetic acid (HY-113413). This product is intended for research and analytical applications. Imidazoleacetic acid (Imidazolyl-4-acetic acid) is a blood-brain barrier-permeable full agonist of the GABA_A receptor. Imidazoleacetic acid forms via histamine oxidation in the mouse brain. Imidazoleacetic acid exerts multiple neurochemical and behavioral effects. Imidazoleacetic acid induces a range of centrally mediated effects, including analgesia, sedation, hypnosis, as well as reductions in blood pressure, body temperature, isolation-induced aggression and motor activity .

Cat. No.	Product Name	Chemical Structure

HY-W654077

Bisphenol AF-d4
Bisphenol AF-d₄ is the isotope labelled analog of Bisphenol AF (HY-W013782). Bisphenol AF is a full agonist for the estrogen receptor. Bisphenol AF acts as an endocrine-disrupting chemical (EDC), activating estrogen through the estrogen receptor Era. Bisphenol AF-d₄ can be used for the research of endocrinology and cancer .

HY-B0659S

Brimonidine-d4
Brimonidine-d₄ is the deuterium labeled Brimonidine. Brimonidine (UK 14304) is a full α2-adrenergic receptor (α2-AR) agonist.

HY-B0188S

Mianserin-d3

Mianserin-d3 is the deuterium labeled Mianserin (HY-B0188). Mianserin (Mianserine) is an orally active H1 receptor antagonist. Mianserin can activate κ-opioid receptor and octopamine receptor. Mianserin increases ERK1/2 and CREB phosphorylation, and antagonizes full κ-opioid agonist and Dynorphin A (HY-P1333)-induced MAPK phosphorylation. Mianserin modulates social and exploratory behaviour, raises electroconvulsive thresholds. Mianserin can be used for the research of neurological disease, such as depression and epilepsy .

HY-15394S

(Rac)-Rotigotine-d7 (hydrochloride)

(Rac)-Rotigotine-d₇ (hydrochloride) is deuterium labeled (Rac)-Rotigotine (hydrochloride). (Rac)-Rotigotine hydrochloride is a racemate of Rotigotine. Rotigotine is a full agonist of dopamine receptor, a partial agonist of the 5-HT1A receptor, and an antagonist of the α2B-adrenergic receptor, with Kis of 0.71 nM, 4-15 nM, and 83 nM for the dopamine D3 receptor and D2, D5, D4 receptors, and dopamine D1 receptor.

HY-B0188AS

Mianserin-d3 hydrochloride

Mianserin-d₃ hydrochloride is the deuterium labeled Mianserin. Mianserin (Mianserine) is an orally active H1 receptor antagonist. Mianserin can activate κ-opioid receptor and octopamine receptor. Mianserin increases ERK1/2 and CREB phosphorylation, and antagonizes full κ-opioid agonist and Dynorphin A (HY-P1333)-induced MAPK phosphorylation. Mianserin modulates social and exploratory behaviour, raises electroconvulsive thresholds. Mianserin can be used for the research of neurological disease, such as depression and epilepsy .

HY-W743727

Cytisine-d4
Cytisine-d₄ is the deuterium labeled Cytisinicline (HY-N0175). Cytisinicline (Cytisine) is an alkaloid. Cytisinicline (Cytisine) is a partial agonist of α4β2 nAChRs , and partial to full agonist at β4 containing receptors and α7 receptors . Has been used medically to help with smoking cessation .

HY-10019S2

Varenicline-13C15N

Varenicline- ¹³C ¹⁵N (CP 526555- ¹³C ¹⁵N) is ¹³C and ¹⁵N labeled Varenicline. Varenicline (CP 526555) is an orally active partial agonist of α4β2 nicotinic acetylcholine receptor (α4β2 nAChR, IC₅₀ = 250 nM), which is the principal mediator of nicotine dependence. Varenicline is also a partial agonist of α6β2 nAChR and a full agonist of α7β2 nAChR. Varenicline blocks the direct agonist effects of nicotine on nAChR while stimulates nAChR in a more moderate way, being widely used as an aid of smoking cessation .

HY-10019S1

Varenicline-15N,13C,d2

Varenicline- ¹⁵N, ¹³C,d₂ is ¹⁵N and deuterated labeled Varenicline (HY-10019). Varenicline (CP 526555) is an orally active partial agonist of α4β2 nicotinic acetylcholine receptor (α4β2 nAChR, IC₅₀=250 nM), which is the principal mediator of nicotine dependence. Varenicline is also a partial agonist of α6β2 nAChR and a full agonist of α7β2 nAChR. Varenicline blocks the direct agonist effects of nicotine on nAChR while stimulates nAChR in a more moderate way, being widely used as an aid of smoking cessation .

HY-10020S

Varenicline-15N3 hydrochloride

Varenicline-15N3 Hydrochloride (CP 526555-15N3 Hydrochloride) is the ¹⁵N labeled isotope of Varenicline hydrochloride (HY-10020). Varenicline (CP 526555) is an orally active partial agonist of α4β2 nicotinic acetylcholine receptor (α4β2 nAChR, IC₅₀ = 250 nM), which is the principal mediator of nicotine dependence. Varenicline is also a partial agonist of α6β2 nAChR and a full agonist of α6β2 nAChR. Varenicline blocks the direct agonist effects of nicotine on nAChR while stimulates nAChR in a more moderate way, being widely used as an aid of smoking cessation .

HY-A0095S

Flibanserin-d4
Flibanserin-d₄ is a deuterium labeled Flibanserin (BIMT-17). Flibanserin is a full agonist of the serotonin 5-HT1A receptor (Ki=1 nM) and an antagonist of 5-HT2A (49 nM) .

HY-10019S

Varenicline-d4

Varenicline-d₄ is deuterium labeled Varenicline. Varenicline (CP 526555) is a potent partial agonist for α4β2 nicotinic acetylcholine receptor (nAChR) with an EC₅₀ value of 2.3 μM. Varenicline is a full agonist for α3β4 and α7 nAChRs with EC₅₀ values of 55 μM and 18 μM, respectively . Varenicline is a nicotinic ligand based on the structure of cytisine, has the potential for smoking cessation treatment .

HY-15394S1

(Rac)-Rotigotine-d3 hydrochloride

(Rac)-Rotigotine-d₃ hydrochloride is a deuterium labeled (Rac)-Rotigotine (hydrochloride) (HY-15394). (Rac)-Rotigotine hydrochloride is a racemate of Rotigotine. Rotigotine is a full agonist of dopamine receptor, a partial agonist of the 5-HT1A receptor, and an antagonist of the α2B-adrenergic receptor, with K_is of 0.71 nM, 4-15 nM, and 83 nM for the dopamine D3 receptor and D2, D5, D4 receptors, and dopamine D1 receptor.

HY-10019AS1

Varenicline-d4 hydrochloride

Varenicline-d₄ hydrochloride is a deuterium labeled Varenicline (dihydrochloride) (HY-10019A) . Varenicline (CP 526555) dihydrochloride is a potent partial agonist for α4β2 nicotinic acetylcholine receptor (nAChR) with an EC₅₀ value of 2.3 μM. Varenicline dihydrochloride is a full agonist for α3β4 and α7 nAChRs with EC₅₀ values of 55 μM and 18 μM, respectively . Varenicline dihydrochloride is a nicotinic ligand based on the structure of cytosine, and has the potential for smoking cessation treatment .

HY-B0584S2

Travoprost-d7
Travoprost-d₇ (Fluprostenol isopropyl ester-d₇) is deuterium labeled Travoprost. Travoprost (Fluprostenol isopropyl ester), an isopropyl ester proagent, is a high affinity, selective FP prostaglandin full receptor agonist. Travoprost has the ocular hypotensive efficacy and has the potential for glaucoma and ocular hypertension .

HY-A0095S1

Flibanserin-d4-1

Flibanserin-d₄-1 is deuterium labeled Flibanserin. Flibanserin (BIMT-17) is a full agonist of the serotonin 5-HT1A receptor (Ki=1 nM) and an antagonist of 5-HT2A (49 nM). Flibanserin binds to dopamine D4 receptors (4-24 nM), and has negligible affinity for a variety of other neurotransmitter receptors and ion channels. Flibanserin is efficacious in treating hypoactive sexual desire disorder (HSDD) .

HY-118504S

Sulfoxaflor-d3

Sulfoxaflor-d₃ is the deuterium labeled Sulfoxaflor (HY-118504). Sulfoxaflor is an orally active full agonist of insect nicotinic acetylcholine receptors (nAChRs), targeting the α-bungarotoxin-insensitive nAChR1 and nAChR2 subtypes. Sulfoxaflor binding to nACh is not inhibited by d-Tubocurarine (HY-125901), but is partially inhibited by Mecamylamine (HY-B1395A). Sulfoxaflor induces inward currents by activating nAChRs, leading to insect neurotoxicity. Sulfoxaflor can be used in the research of agricultural pest control, pesticide toxicology, insect neural receptor pharmacology, etc .

HY-135581S1

Raloxifene 6-glucuronide-d4 lithium

Raloxifene 6-glucuronide-d₄ (lithium) is deuterium labeled Raloxifene 6-glucuronide. Raloxifene 6-glucuronide is a primary metabolite of Raloxifene. Raloxifene 6-glucuronide is mediated mostly by UGT1A1 and UGT1A8. Raloxifene 6-glucuronide binds to estrogen receptor with an IC₅₀ of 290 μM. Raloxifene is a selective and nonsteroidal estrogen receptor modulator. Raloxifene activates TGFβ3 promoter as a full agonist at nanomolar concentrations, and inhibits the estrogen response element-containing vitellogenin promoter expression .

HY-135582S1

Raloxifene 4'-glucuronide-d4 lithium

Raloxifene 4'-glucuronide-d₄ (lithium) is deuterium labeled Raloxifene 4'-glucuronide. Raloxifene 4'-glucuronide is a primary metabolite of Raloxifene. Raloxifene 4'-glucuronide formation is mediated mostly by UGT1A10 and UGT1A8. Raloxifene 4'-glucuronide binds to estrogen receptor with an IC₅₀ of 370 μM. . Raloxifene is a selective estrogen receptor modulator. Raloxifene activates TGFβ3 promoter as a full agonist at nanomolar concentrations, and inhibits the estrogen response element-containing vitellogenin promoter expression .

HY-135582S

Raloxifene 4'-glucuronide-d4

Raloxifene 4'-glucuronide-d₄ is deuterated labeled Raloxifene 4'-glucuronide (HY-135582). Raloxifene 4'-glucuronide is a primary metabolite of Raloxifene. Raloxifene 4'-glucuronide formation is mediated mostly by UGT1A10 and UGT1A8. Raloxifene 4'-glucuronide binds to estrogen receptor with an IC₅₀ of 370 μM. . Raloxifene is a selective estrogen receptor modulator. Raloxifene activates TGFβ3 promoter as a full agonist at nanomolar concentrations, and inhibits the estrogen response element-containing vitellogenin promoter expression .

HY-100658S

Didesmethyl cariprazine-d8

Didesmethyl cariprazine-d₈ is the deuterium labeled Didesmethyl cariprazine (HY-100658). Didesmethyl cariprazine is an orally active, BBB-permeable metabolite of Cariprazine (HY-14763). Didesmethyl cariprazine is a partial agonist at the D2 and D3 receptors, full agonist at the 5-HT1A receptor, and antagonist at the human 5-HT2B receptor (K_i: 1.41 nM (human D2L), 0.056 nM (human D3), 1.7 nM (human 5-HT1A), 0.52 nM (human 5-HT2B)). Didesmethyl cariprazine dose-dependently inhibits the spontaneous activity of rat midbrain dopaminergic neurons.

Cat. No.	Product Name		Classification

HY-128855

Talsaclidine		Alkynes
Talsaclidine is a muscarinic agonist with preferential neuron-stimulating properties. Talsaclidine is a full agonist at the M1 subtype, and as a partial agonist at the M2 and M3 subtypes . Talsaclidine is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.

Inquiry Online

Your information is safe with us. * Required Fields.

MCE Japan Authorized Agent ナミキ商事株式会社コスモ・バイオ株式会社重松貿易株式会社
Salutation			Country or Region *
Applicant Name *			Organization Name *
Department *
Email Address *			Product Name *
Cat. No.			Requested quantity *
Phone Number *
Remarks